TL;DR
CRISPR/Cas gene editing holds immense promise for gene therapy, but delivering these powerful tools safely and effectively into cells remains a major hurdle. This review explores the latest advancements in carrier strategies, focusing on how various delivery systems can protect CRISPR components, enhance their targeting, and ultimately boost their clinical application.
What Problem Does This Paper Address?
The CRISPR/Cas system is a revolutionary technology for precise genome editing, offering unprecedented potential for treating genetic diseases. However, the inherent instability of CRISPR components (proteins and nucleic acids) in the body, coupled with their poor ability to cross cell membranes, significantly limits their therapeutic application. This paper addresses the critical challenge of developing effective and safe delivery systems for CRISPR/Cas components, aiming to overcome these limitations and pave the way for widespread clinical use.
Methods
This review synthesizes existing research on CRISPR/Cas delivery systems, categorizing them based on the format of the CRISPR cargo:
- Cas9 Ribonucleoprotein (RNP) complexes: These consist of the Cas9 protein pre-assembled with a single-guide RNA (sgRNA).
- Cas9 mRNA and sgRNA: Delivering the genetic instructions for Cas9 production and the guide RNA separately.
- Cas9 plasmid: Delivering the DNA encoding Cas9 and sgRNA, which then needs to be transcribed and translated within the cell.
The paper discusses two primary categories of delivery strategies:
- Viral vectors: Including lentiviruses (LVs), adenoviruses (AVs), and adeno-associated viruses (AAVs). These are well-established for gene delivery but face challenges like immunogenicity and limited packaging capacity.
- Nanomaterial-based carriers: A rapidly developing area encompassing lipid nanoparticles (LNPs), polymers, gold nanoparticles, and other inorganic nanoparticles. These offer advantages like lower immunogenicity, tunable properties, and the potential for targeted delivery.
The review details various approaches to improve delivery, including modifying the CRISPR components themselves (e.g., adding nuclear localization signals to Cas9) and engineering the carriers for better cellular uptake, endosomal escape, and targeted release.
Datasets
Not discussed in the paper. This is a review article summarizing existing research, not a primary research paper presenting new experimental data.
Key Insights and Ideas
- The "delivery problem" is paramount: While CRISPR/Cas technology is powerful, its clinical translation hinges on solving the delivery challenge. Without effective carriers, the system's potential remains largely untapped.
- No one-size-fits-all solution: Different CRISPR cargo formats (RNP, mRNA, plasmid) and target applications necessitate distinct delivery strategies. RNPs offer transient editing with reduced off-target effects, while plasmids can lead to stable expression but carry integration risks.
- Nanomaterials are emerging as strong contenders: Beyond viral vectors, nanomaterials offer a promising avenue for safer and more versatile CRISPR delivery, with ongoing innovation in lipid-based nanoparticles, polymers, and inorganic nanostructures.
- Targeting and safety are key: Future delivery systems must not only efficiently deliver CRISPR components but also target specific tissues and cells while minimizing immunogenicity and off-target effects.
- HDR delivery remains a significant challenge: While NHEJ-mediated gene knockout is more readily achieved, delivering CRISPR components and donor DNA for homology-directed repair (HDR) for gene correction is considerably more difficult and less efficient.
Key Results
This review doesn't present new quantitative results but summarizes the state-of-the-art in CRISPR delivery, highlighting:
- Viral vectors (LVs, AVs, AAVs): Demonstrated efficacy in preclinical and some clinical settings, but face limitations like immunogenicity and insertional mutagenesis.
- Nanomaterial-based carriers: Show promise for improved safety and versatility. Specific examples include:
- Lipid Nanoparticles (LNPs): Successfully used for mRNA delivery (e.g., COVID-19 vaccines) and are being adapted for CRISPR components.
- Cationic Polymers: Effective in forming polyplexes with CRISPR components for intracellular delivery.
- Gold Nanoparticles (AuNPs): Utilized for RNP delivery and HDR, showing potential for in vivo gene editing.
- Clinical Trials: Approximately 50 clinical trials are underway, primarily focusing on adoptive cell therapies and in vivo gene editing, with viral vectors and LNPs being the most prevalent delivery methods.
Limitations and Future Work
The authors acknowledge several limitations and suggest future directions:
- Low delivery efficiency: Despite advancements, the efficiency of non-viral delivery systems, particularly for RNP and plasmid delivery, remains a significant hurdle.
- Off-target effects and immunogenicity: While carriers aim to mitigate these, further research is needed to ensure long-term safety and minimize unintended consequences.
- HDR delivery: Co-delivery of CRISPR components and donor DNA for HDR is still inefficient and requires substantial improvement for therapeutic applications.
- In vivo evaluation: Many promising nanomaterial-based systems require more extensive in vivo studies to assess their efficacy, biosafety, and scalability.
- Standardization: The development of standardized protocols for CRISPR delivery systems is crucial for their translation into clinical practice.
- Combination therapies: Exploring the use of CRISPR delivery systems in conjunction with other therapeutic modalities (e.g., photothermal therapy) holds promise.
Summary updated